

SECOND LINE CHEMOTHERAPY WITH NAB-PACLITAXEL IN PATIENTS WITH PANCREAS CANCER


Alonso Castellanos S¹, Romero Jimenez RM², Ubeira Iglesias M¹, Briones Cuesta E¹, Pedrosa Naudín MA¹, Oca Luis B¹, López Ínsua A¹, Martínez de Arriba R¹, Barbadillo Villanueva S¹, Güemes García M¹. 1.Hospital Universitario de Burgos, Pharmacy Department. Burgos (Spain). 2. Hospital General Universitario Gregorio Marañón, Pharmacy Department. Madrid (Spain)

Background

Pancreatic cancer is one of the most deadly forms of cancer. Standard treatment in metastatic disease is the chemotherapy with gemcitabine, but there is not a standard therapy for gemcitabine-refractory patients.

Purpose

Assess the off-label efficacy of nab-paclitaxel (Abraxane®), in patients who progressed on gemcitabine-based therapy, in our hospital.




Material and Methods

Observational and retrospective study of pancreatic cancer patients treated with nab-paclitaxel who progressed on gemcitabine-based therapy from June 2011 to April 2012. We determined: Progression Free Survival (PFS) and Overall Survival (OS). 12 patients (100% male) were treated with nab-paclitaxel. 11 of them presented metastatic disease.


The patients were treated with two therapies:

- Nab-paclitaxel 100mg/m² (1,8,15/28d). 5 patients received this treatment. Median age was 79,4 years (SD= 4,2 years).
- Gemcitabine 1000mg/m² plus nab-paclitaxel 100mg/m² (1,8,15/28d): 7 patients received this treatment. Median age was 65,5 years (SD= 6,9years).

Median PFS was 2,8 months (95% CI, 1.5 to 4.1 months) with single agent, and 5,3 months (95% CI, 4.0 to 6,5 months) with gemcitabine plus nab-paclitaxel. The PFS in the study was 20% and 83% respectively. The OS couldn't be determined in the nab-paclitaxel group, because there was not any event during the study period. The OS with gemcitabine plus nab-paclitaxel was 66,7%.



Progression free survival (PFS)



Overall Survival (OS)

Conclusions

- ❖ It showed better clinical outcomes in the gemcitabine plus nab-paclitaxel group in PFS.
- ❖ The nab-paclitaxel can be an effective second-line chemotherapy in gemcitabine resistant patients.